Chemotherapy, neurotoxicity, and cognitive changes in breast cancer

Journal of Cancer Research and Therapeutics

Volumn 7, Issue 3, 2011, Pages 264-269

  Dutta, Varsha ^a  

^a DR BALABHAI NANAVATI HOSPITAL   (India)

Author keywords

Breast cancer; chemofog; chemotherapy; frontostriatal dysfunction; neurotoxicity

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; THIOTEPA;

ANXIETY; ATTENTION DISTURBANCE; BRAIN REGION; BRAIN SIZE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVOR; CLINICAL DECISION MAKING; COGNITIVE DEFECT; CORRELATION ANALYSIS; DEPRESSION; DRUG MEGADOSE; HUMAN; LEARNING DISORDER; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NONHUMAN; REVIEW; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; NERVOUS SYSTEM DISEASES; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES;

EID: 81855173584     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.87008     Document Type: Review

References (56)

1. Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007;7:192-201.
2. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: A review of published studies and recommendations for future research. J Clin Oncol 2007;25:2455-63. (Pubitemid 46999217)
3. Bender CM, Pacella ML, Sereika SM, Brufsky AM, Vogel VG, Rastogi P, et al. What do perceived cognitive problems reflect? J Support Oncol 2008;6:238-42. (Pubitemid 351836613)
4. Poppelreuter M, Weis J, Külz AK, Tucha O, Lange KW, Bartsch HH. Cognitive dysfunction and subjective complaints of cancer patients: A cross-sectional study in a cancer rehabilitation centre. Eur J Cancer 2004;40:43-9. (Pubitemid 37542316)
5. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004;26:955-69. (Pubitemid 39577316)
6. Meyers CA. How chemotherapy damages the central nervous system. J Biol 2008; 7: 11
7. Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485-93. (Pubitemid 34072533)
8. van Dam FS, Schagen SB, Muller MJ, Boogerd W, vd Wall E, Droogleever Fortuyn ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-8. (Pubitemid 28114539)
9. Schagen SB, Muller MJ, Boogerd W, Millenbergh GJ, van Dam FS. Change in Cognitive Function After Chemotherapy: A Prospective Longitudinal Study in Breast Cancer Patients. J Natl Cancer Inst 2006;98:1742-5. (Pubitemid 44942713)
10. Debess J, Riis JE., Engebjerg MC, Ewertz M. Cognitive function after adjuvant treatment for early breast cancer: A population-based longitudinal study. Breast Cancer Res Treat 2010;121:91-100.
11. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005;59:60-70. (Pubitemid 41405841)
12. Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive junction in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-701. (Pubitemid 30463551)
13. Joshi G, Sultana R, Tangpong J, Cole MP, St Clair DK, Vore M, et al. Free radical mediated oxidative stress and toxic side effects in brain induced by the anti cancer drug adriamycin: Insight into chemobrain. Free Radical Res 2005;39:1147-54. (Pubitemid 41601416)
14. Komaki R, Meyers CA, Shin DM, Garden AS, Byrne K, Nickens JA, et al. Evaluation of cognitive function in patients with limited small cell lung cancer prior to and shortly following prophylactic cranial irradiation. Int J Radiat Oncol Biol Phys 1995;33:179-82.
15. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-50. (Pubitemid 29075285)
16. Wefel JS, Lenzi R, Theriault R, Davis RN, Meyers CA: The cognitive sequelae of standard dose adjuvant chemotherapy in women with breast cancer: Results of a prospective, randomized, longitudinal trial. Cancer 2004;100: 2292-9. (Pubitemid 38657875)
17. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 1995;4:61-6. (Pubitemid 26093776)
18. Winocur G, Vardy J, Binns MA, Kerr L, Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil on cognitive function in mice. Pharmacol Biochem Behav 2006;85: 66-75. (Pubitemid 44802737)
19. Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in North India. Indian J Can 2010;47:16-22.
20. Pandey M, Gangadharan PS, Devi N, Thomas BC, Hussain BM, Krishnan R. Distress, anxiety, and depression in cancer patients undergoing chemotherapy. World J Surg Oncol 2006;4:68.
21. Senf B, Brandt H, Dignass A, Kleinschmidt R, Kaiser J. Psychosocial distress in acute cancer patients assessed with an expert rating scale. Support Care Cancer 2010;18:957-65.
22. Chintamani, Gogne A, Khandelwal R, Tandon M, Jain S, Kumar Y, et al. The correlation of anxiety and depression levels with response to neoadjuvant chemotherapy in patients with breast cancer. JRSM Short Rep 2011;2:15.
23. Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K, et al. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 2005;12:279-87.
24. Marín AP, Sánchez AR, Arranz EE, Auñón PZ, Barón MG. Adjuvant Chemotherapy for Breast Cancer and Cognitive Impairment. South Med J 2009;102:929-34.
25. Weiss B. Chemobrain: A translational challenge for neurotoxicology. Neurotoxicology 2008;29:891-8.
26. Collie A, Darekar A, Weissgerber G, Toh MK, Snyder PJ, Maruff P, et al. Cognitive testing in early-phase clinical trials: Development of a rapid computerized test battery and application in a simulated phase I study. Contemp Clin Trials 2007;28:391-400. (Pubitemid 46755022)
27. Fray PJ, Robbins TW. CANTAB battery: Proposed utility in neurotoxicology. Neurotoxicol Teratol 1996;18:499-504. (Pubitemid 26288719)
28. Ferreira FN, Andrade AG, Alves TC. Neuroimaging Findings in Breast Cancer: A Systematic Qualitative Review. Intl J Med Sci 2009;1:442-7.
29. Matsuoka Y, Yamawaki S, Inagaki M, Akechi T, Uchitomi Y. A volumetric study of amygdala in cancer survivors with intrusive recollections. Biol Psychiatry 2003;54:736-43. (Pubitemid 37281390)
30. Yoshikawa E, Matsuoka Y, Inagaki M, Nakano T, Akechi T, Kobayakawa M, et al. Prefrontal cortex and amygdala volume in first minor or major depressive episode after cancer diagnosis. Biol Psychiatry 2006;59:707-12.
31. Eberling JL, Wu C, Tong-Turnbeaugh R, Jagust WJ. Estrogen and tamoxifen-associated effects on brain structure and function. Neuroimage 2004;21:364-71. (Pubitemid 38115027)
32. Hara E, Matsuoka Y, Hakamata Y, Nagamine M, Inagaki M, Imoto S, et al. Hippocampal and amygdalar volumes in breast cancer survivors with posttraumatic stress disorder. J Neuropsychiatry Clin Neurosci 2008;20:302-8.
33. Nakano T, Wenner M, Inagaki M, Kugaya A, Akechi T, Matsuoka Y, et al. Relationship between distressing cancer-related recollections and hippocampal volume in cancer survivors. Am J Psychiatry 2002;159:2087-93. (Pubitemid 35423870)
34. Inagaki M, Yoshikawa E, Matsuoka Y, Sugawara Y, Akechi TT, Wada N, et al. Smaller Regional Volumes of Brain Gray and White Matter Demonstrated in Breast Cancer Survivors Exposed to Adjuvant Chemotherapy. American Cancer Society. Cancer 2007; 109:146-56. (Pubitemid 46120202)
35. Phillips KA, Bernhard J. Adjuvant breast cancer treatment and cognitive function: Current knowledge and research directions. J Natl Cancer Inst 2003;95:190-7. (Pubitemid 36240631)
36. Ernst T, Chang L, Cooray D, Salvador C, Jovicich J, Walot I, et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 2002;94:592-7. (Pubitemid 34498646)
37. Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007;103:303-11. (Pubitemid 46944511)
38. Kim LS, Hwang HS, Jon DI, Ham BJ, Seok JH. Dysfunction of the neural network associated with sustained attention in cancer patients with clinically significant depressive symptoms. Neurosci Lett 2008;5;447:1-6.
39. Yoshikawa E, Matsuoka Y, Inagaki M, Nakano T, Akechi T, Kobayakawa M, et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 2005;92:81-4. (Pubitemid 40875082)
40. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol 1995;6:489-94.
41. van Gerven JM, Moll JW, van den Bent MJ, Bon tenbal M, van der Burg ME, Verweij J, et al. Paclitaxel (Taxol) induces cumulative mild neurotoxicity. Eur J Cancer 1994;30A:1074-7.
42. Tangpong J, Cole MP, Sultana R, Joshi G, Estus S, Vore M, et al. Adriamycin-induced, TNF-alpha-mediated central nervous system toxicity. Neurobiol Dis 2006;23:127-39. (Pubitemid 44192385)
43. Chandrashekara S, Jayashree K, Veeranna HB, Vadiraj HS, Ramesh MN, Shobha A, et al. Effects of anxiety on TNF-alpha levels during psychological stress. J Psychosom Res 2007;63:65-9. (Pubitemid 46935800)
44. Johnson EO, Kamilaris TC, Chrousos GP, Gold PW. Mechanisms of stress: A dynamic overview of hormonal and behavioral homeostasis. Neurosci Biobehav Rev 1992;16:115-30.
45. Wiedenmayer CP, Bansal R, Anderson GM, Zhu H, Amat J, Whiteman R, et al. Cortisol levels and hippocampus volumes in healthy preadolescent children. Biol Psychiatry 2006;60:856-6
46. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925-35.
47. Young EA, Vazquez D. Hypercortisolemnia, hippocampal glucocorticoid receptors, and fast feedback. Mol Psychiatry 1996;1:149-59. (Pubitemid 126442405)
48. McEwen BS. Stress and hippocampal plasticity. Annu Rev Neurosci 1999;22:105-22. (Pubitemid 29144882)
49. Dietrich J, Han R, Yang Y, Mayer-Pröschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006;5:22.
50. Reiriz AB, Reolon GK, Preissler T, Rosado JO, Henriques JA, Roesler R, Schwartsmann G: Cancer chemotherapy and cognitive function in rodent models: Memory impairment induced by cyclophosphamide in mice. Clin Cancer Res 2006;12:5000. (Pubitemid 44338589)
51. Han R, Yang YM, Dietrich J, Luebke A, Mayer-Pröschel M, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J Biol 2008;7: 12.
52. Kreukels BP, Hamburger HL, de Ruiter MB, van Dam FS, Ridderinkhof KR, Boogerd W, et al. ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. Clin Neurophysiol 2008;119: 533-41.
53. McPherson K, Steel CM, Dixon JM. Breast cancer-epidemiology, risk factors, and genetics. BMJ 2000;321:624-8.
54. Bagchi S. Breast cancer rises in India. CMAJ 2008;179: 27.
55. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer J Clin 2011;61:69-90.
56. Meherishi S, Khandelwal S, Swarankar ML, Kaur P. Attitudes and practices of gynecologists in Jaipur toward management of menopause. J Midlife Health 2010;1:74-8.